AbbVie stock jumps after $700 million licensing deal with IGI Therapeutics By Investing.com

AbbVie stock jumps after $700 million licensing deal with IGI Therapeutics

LVM Capital Management Dumps 16,000 ICON Public Shares Worth $2.6 million

Key PointsLVM Capital Management shed 16,096 shares valued at $2.58 million.LVM now holds 40,603 ICON shares valued at $5.91 million.ICON is a mid-sized position for LVM, now representing 0.61% of the fund.These 10 stocks could mint the next wave of millionaires › What happenedAccording to an SEC filing dated July 2, 2025, LVM Capital Management reduced its position in ICON Public Limited (NASDAQ:ICLR) by selling 16,096 shares. The transaction was valued at $2.58 million. After the trade, the fu...

3 No-Brainer Stocks to Buy in July

Key PointsAbbVie offers something for every investor.Eli Lilly could be overdue for a big rally.Vertex Pharmaceuticals is in a new era, but should continue to be a big winner for investors. Dont let the summer heat keep you from making money. July is a great time to invest in the stocks of top-tier companies. Three Motley Fool contributors think theyve found no-brainer stocks to buy this month. Heres why they picked healthcare stocks AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), and Vertex Phar...

2 Dividend Stocks to Buy for Decades of Passive Income

Key PointsHealthcare giants AbbVie and Abbott Laboratories are both Dividend Kings.They should maintain their dividend growth habits for a long time to come.Thats thanks to their solid businesses and promising product pipelines. In 2013, AbbVie (NYSE: ABBV) became a publicly traded corporation after splitting from its former parent company, Abbott Laboratories (NYSE: ABT). Since then, both have produced strong returns and have been great picks for income-seeking investors, thanks to consistent ...

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever

Key PointsAbbVie is a Dividend King with solid growth prospects.Enbridge is a leading pipeline operator and natural gas utility with an ultra-high dividend yield.Realty Income pays monthly dividends that are highly reliable. Theres a strong parallel between investing for passive income and planting an apple tree. Both require some work up front. But if all goes well, you can reap the fruits of those labors (literally, in the case of the apple tree) for years afterward. Of course, there are some...

AbbVie: Q2 Earnings Warning Reflects Poor R&D, But Its Not A Red Flag

Is It Worth Investing in AbbVie (ABBV) Based on Wall Streets Bullish Views?

According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Can Buying the Vanguard S&P 500 ETF Make You a Millionaire?

Buying an exchange-traded fund (ETF) that tracks an index like the S&P 500 can be a great way to build long-term wealth, and this strategy is endorsed by some of the worlds top investors, including Warren Buffett. The Vanguard S&P 500 ETF (NYSEMKT: VOO) is one of the most popular funds on the market because of its super low cost, and it could certainly make you a millionaire with regular contributions and the right time horizon. Below, Ill break down the components of the Vanguard S&P 500 ETF ...

The Zacks Analyst Blog Highlights Alphabet, AbbVie and The Walt Disney

GOOGL, ABBV, and DIS face rising costs and competition, but strong cloud, immunology, and parks growth continue to fuel optimism.

HDV Is a Popular Dividend ETF for Passive Income. But Is It the Best?

Artificial intelligence (AI), big tech, and cryptocurrencies all have their fans among investors, and with good reason. All can add to a well-balanced portfolio that will help make you richer over time. But you shouldnt forget about income investing -- buying stocks that reward you for holding them by paying a nice, sizable dividend on a regular basis. Rather than trying to pick one or two (or 12) dividend stocks, many investors turn to exchange-traded funds (ETFs) to do the heavy lifting. Divi...

Abbvie confirms $2.1B Capstan swoop

Abbvie Inc (NYSE:ABBV) has agreed to acquire Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its pipeline with a potential first-in-class...

Abbvie confirms $2.1bn Capstan swoop

Abbvie Inc (NYSE:ABBV) has agreed to acquire Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its pipeline with a potential first-in-class...

DGRO Is a Popular Dividend ETF for Passive Income, but Is It the Best?

Many, if not most, of us would do well to include a bunch of dividend payers in our portfolio. Naturally, if were retired, we can use that regular income to pay for living expenses. But even if were much younger and still working, dividends can be extremely useful. For example, at times when you dont have any extra cash with which to invest, youll still be collecting dividend money, which can be used to buy more shares of stock for your long-term portfolio. A particularly easy way to invest ...

3 Dividend Stocks to Double Up on Right Now

Buy, sell, or hold? Thats the question investors must continually ask about each stock in their portfolio. The correct answer might be to sell if your original investing thesis has changed. In many cases, the best course of action is to simply stay the course. Sometimes, though, adding more to your position makes sense.Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Every now and then, the smartest strategy i...

Got $500? 2 Healthcare Stocks to Buy and Hold Forever

I dont know if well be riding in personal aircraft 20 years from now, like George Jetson did in the cartoon TV series. I dont know if artificial intelligence (AI) will replace millions of jobs. But theres one thing Im quite confident about: Well still need healthcare products and services in the future, whether were talking about 10 or 100 years from now. The healthcare sector is an ideal place for long-term investors to focus their attention, in my view. The trick is to find the stocks o...

AbbVie (ABBV) Stock Dips While Market Gains: Key Facts

AbbVie (ABBV) closed at $182.31 in the latest trading session, marking a -2.4% move from the prior day.

5 Vanguard ETFs to Buy With $1,000 and Hold Forever

Investing in exchange-traded funds (ETFs) is a great way for both new and experienced investors to gain market exposure, and Vanguard is one of the best places to begin, given that the investment firm is known as the low-cost leader. A $1,000 investment is a good starting point, although one key to building wealth is to consistently add to your investments over time through a dollar-cost averaging strategy. Among the variety of ETFs that Vanguard offers, theres something to fit nearly every inv...

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Heres Why AbbVie (ABBV) Fell More Than Broader Market

In the most recent trading session, AbbVie (ABBV) closed at $185.48, indicating a -2.82% shift from the previous trading day.

Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trumps plan

The lawmakers accuse Pfizer, Merck, J&J, AbbVie and Amgen of paying little to nothing in federal taxes despite generating billions of dollars annually.

Pfizer, AbbVie und Co unter Druck: Trump mit dem nächsten Hammer?

US-Präsident Donald Trump will der Pharma-Industrie weiter an den Kragen gehen. Laut Kreisen möchte der Republikaner die Pharmawerbung in den Vereinigten Staaten einschränken. Nach einer generellen Sektorschwäche am Montag zeichnen sich bei vielen Pharma- und Biotech-Titeln am Dienstag weitere Verluste ab.

Pfizer, AbbVie und Co unter Druck: Trump mit dem nächsten Hammer?

US-Präsident Donald Trump will der Pharma-Industrie weiter an den Kragen gehen. Laut Kreisen möchte der Republikaner die Pharmawerbung in den Vereinigten Staaten einschränken. Nach einer generellen Sektorschwäche am Montag zeichnen sich bei vielen Ph...

AbbVies Venclexta Misses Goal in Myelodysplastic Syndromes Study

Venclexta fails to meet survival goals in ABBVs phase III MDS study, marking another clinical setback for the cancer drug.

AbbVies Diversification Strategy Cushions Venetoclax MDS Blow

AbbVie fails in late-stage trial for Roche-partnered blood cancer therapy venetoclax

5 Large Drug Stocks That Are Poised to Ride on Sector Recovery

In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.

2 High-Yielding ETFs That Can Generate Dividend Income for Your Portfolio for Decades

Investing in dividend stocks is a great way to generate a steady stream of recurring income for your portfolio. But ideally, you dont invest in just one or two dividend stocks, because then you run the risk of a dividend cut or suspension suddenly affecting the income that youve been relying on. To diversify and to minimize your overall risk, its better to invest in an exchange-traded fund (ETF) that pays dividends. With an ETF that invests in dozens of dividend stocks, you get some valuable ...

AbbVie (ABBV) Gains As Market Dips: What You Should Know

The latest trading day saw AbbVie (ABBV) settling at $191.50, representing a +1.06% change from its previous close.

AbbVie Inc. (ABBV) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

AbbVie at Goldman Sachs Conference: Strategic Growth and Innovation By Investing.com

AbbVie at Goldman Sachs Conference: Strategic Growth and Innovation